1061/1644US=56 / Biol/Mol
Vega CJ. Laser microdissection sample preparation for RNA analyses. In: Mor G, Alvero AB. Apoptosis and cancer: methods and protocols. New Jersey: Humana Press, 2008. p. 241-52. (Methods in Molecular Biology) ISBN 978-1-58829-457-9.

MICRODISSECCAO A LASER; MICRODISSECCAO E CAPTURA A LASER (MCL); EXPRESSAO GENICA; RNA; RNASE


1062/1644US=64 / Câncer
Mitsiades CS, Hideshima T, Munshi NC, Richardson PG, Anderson KC. The role of heat shock protein 90 as a therapeutic target for multiple myeloma. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 291-308. (Comtemporary Hematology) ISBN 978-1-934115-82-4.

TERAPEUTICO PARA O MIELOMA MULTIPLO; CHAPERONE MOLECULAR UBIQUAMENTE


1063/1644US=67 / Biol/Mol
Knights CD, Pestell RG. The cell cycle: therapeutic targeting of cell regulatory components and effector pathways in cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 3-32. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CICLO CELULAR; SEGMENTACAO TERAPEUTICA; COMPONENTES CELULARES; VIAS REGULADORAS; CANCER; CICLINA DEPENDENTE DE QUINASE; INIBIDORES CDK; TERAPIA; ACETILACAO; P53; CICLINA D1; EGFR; HDAC; STI-571; FLAVOPIRIDOL; INIBIDOR CDK2


1064/1644US=67 / Biol/Mol
Easton JB, Houghton PJ. mTOR: properties and therapeutics. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 33-53. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

MTOR; PROPRIEDADES; TERAPEUTICA; INIBIDORES; RAPAMICINA; CANCER; ENSAIOS CLINICOS


1065/1644US=67 / Biol/Mol
Sparano JA. Ras/Raf/MEK inhibitors. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 55-73. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

INIBIDORES; RAS; RAF; MEK


1066/1644US=67 / Biol/Mol
Neckers L, Ivy P. 17-AAG: targeting the molecular chaperone heat shock protein 90. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 75-95. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

17-AAG; CHAPERONE; PROTEINA DE CHOQUE TERMICO 90; CANCER; CHAPERONE MOLECULAR; TERAPIA ALVO; PLASTICIDADE GENETICA; ONCOGENE; GELDANAMICINA; ANSAMICINA BENZOQUINONA


1067/1644US=67 / Biol/Mol
Thiagalingam S, Faller DV. The cancer epigenome: cann it be targeted for therapy?. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 97-113. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER; EPIGENOMA; METILACAO DO DNA; DNA METIL TRANSFERASE; HISTONA ACETILTRANSFERASE; HISTONA-DESACETILASE; CODIGO DE HISTONAS; CODIGO EPIGENOMICO ATIVA; CODIGO EPIGENOMICO SILENCIADO; INIBIDOR DE HISTONA-DESACETILASE; TERAPIA DO CANCER


1068/1644US=67 / Biol/Mol
Wadler S. Molecular targeting in upper gastrointestinal malignancies. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 117-31. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

NEOPLASIAS GASTROINTESTINAIS SUPERIORES; SEGMENTACAO MOLECULAR; CARCINOMA HEPATOCELULAR; CANCER DE PANCREAS; CANCER DE ESTOMAGO; TERAPIA-ALVO


1069/1644US=67 / Biol/Mol
Sundermeyer ML, Bellacosa A, Meropol NJ. Molecular targeting of colorectal cancer: an idea whose time has come. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 117-31. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER COLORRETAL; SEGMENTACAO MOLECULAR; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR


1070/1644US=67 / Biol/Mol
Schwartz JD, Llovet JM. Molecular targeting in hepatocellular carcinoma. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 165-210. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CARCINOMA HEPATOCELULAR; ALVO MOLECULAR; TERAPEUTICA ANTI-ANGIOGENESE; FATORES DE CRESCIMENTO


1071/1644US=67 / Biol/Mol
Goel A, Kozuch P. Molecularly targeted therapy in pancreatic cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 211-26. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER DE PANCREAS; TERAPIA ALVO MOLECULAR; BEVACIZUMABE; CETUXIMABE; ERLOTINIBE; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); TERAPIA ANTI-ANGIOGENICA


1072/1644US=67 / Biol/Mol
Ho C, Davies AM, Lara PN, Gautschi O, Mach PC, Gumerlock PH, Gandara DR. Untargeted use of targeted therapy: a dilemma in non-small cell lung cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 227-40. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER DE PULMAO DE CELULAS NAO-PEQUENAS; TERAPIA-ALVO; EGFR; VEGF; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL


1073/1644US=67 / Biol/Mol
Hahn O, Stadler W. Renal cell carcinoma: renal cell cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 241-61. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CARCINOMA DE CELULAS RENAIS; CANCER DE CELULAS RENAIS; TERAPIA MOLECULAR


1074/1644US=67 / Biol/Mol
Heath EI, Carducci MA. Targeted therapies for prostate cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 263-90. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER DE PROSTATA; TERAPIA-ALVO; INIBIDORES DA VIA DE SINALIZACAO; INIBIDORES DA ANGIOGENESE; IMUNOTERAPIA; AGENTES ANTI-TUBULINA; AGENTES ANTI-MITOTICOS; AGENTES DE SEGMENTACAO ANTI-VASCULARES


1075/1644US=67 / Biol/Mol
Azad NS, Sarosy G, Kohn EC. Molecular targets in ovarian cancer and endometrial cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 291-308. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER DE OVARIO; CANCER ENDOMETRIAL; ALVOS MOLECULARES; TIROSINA-QUINASES; EGFR; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); ONCOGENE; GENES SUPRESSORES DE TUMOR


1076/1644US=67 / Biol/Mol
Atieh DM, Vahdat LT. Targeted therapy for beast cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 309-42. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER DE MAMA; TERAPIA-ALVO; TRASTUZUMABE; HER-2; MICROARRAY; BEVACIZUMABE; VEGF; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; LAPATINIBE; ANTICORPOS MONOCLONAIS; INIBIDOR DA TIROSINA QUINASE


1077/1644US=67 / Biol/Mol
Gupta A, Kirkwood JM. Melanoma. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 343-67. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

MELANOMA; PATOGENESE MOLECULAR; TERAPIA ALVO; INTERFERON; STAT; ANTISENSE BC12; BRAF; APOPTOSE; CICLO CELULAR


1078/1644US=67 / Biol/Mol
Borghaei H, Binyamin L, Astsaturov I, Weiner LM. Antibody therapy of cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 371-412. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER. TERAPIA; ANTICORPOS MONOCLONAIS; TERAPIA DE ANTICORPOS; CITOTOXICIDADE CELULAR DEPENDENTE DE ANTICORPO; CITOTOXICIDADE DEPENDENTE DE COMPLEMENTO; IMUNOCONJUGADOS


1079/1644US=67 / Biol/Mol
Vogl DT, Gewirtz AM. Nucleic acid therapies for cancer treatment. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 413-29. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CANCER. TERAPIA; ACIDO NUCLEICO; OLIGONUCLEOTIDEOS ANTISENSE; DNA; RNAI


1080/1644US=67 / Biol/Mol
Nakamura T, Russell SJ. Engineering oncolytic measles viruses for targeted cancer therapy. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 431-45. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

VIRUS ONCOLITICOS; SARAMPO; TERAPIA DE CANCER; TERAPIA-ALVO; VIROTERAPIA


Primeira | Anterior | Próxima | Última